The merger addresses the stockholders' equity deficiency but does not cure the bid price rule violation — the reverse split vote at the May 8 special meeting remains critical. Monitor for the Nasdaq Hearings Panel's formal determination on compliance and any definitive proxy supplement adding the stockholder approval proposal for conversion. The $1.50 conversion price represents a significant premium to the current sub-$1.00 stock price, making near-term conversion unlikely even if approval is obtained.
Price Chart
Executive Summary
Lunai Bioworks completed a triangular merger to acquire a multi-jurisdictional CNS patent portfolio from Oncotelic and Pelerin Therapeutics, issuing $20M in Series B convertible preferred stock as consideration. The transaction is the company's primary effort to regain compliance with Nasdaq's $2.5M stockholders' equity requirement, though the company remains at risk of delisting pending the Panel's formal determination and continued compliance with the bid price rule. The Series B shares are non-convertible until stockholder approval is obtained, and the patents have no associated revenue or operations.
Key Financial Metrics
Key Facts
- Acquired a multi-jurisdictional patent portfolio (the 'Patents') directed to CNS therapeutics via merger with Neurobridge IP Holdings
- Issued 8 shares of Series B Convertible Preferred Stock with an aggregate stated value of $20,000,000 as consideration; no cash paid
- Series B Preferred Stock is convertible into 13,333,333 shares of common stock at $1.50/share, but only after stockholder approval under Nasdaq Rule 5635
- Company was facing delisting from Nasdaq for failure to meet the $2.5M stockholders' equity rule (Rule 5550(b)(1)) and the $1.00 bid price rule (Rule 5550(a)(2))
- Company believes the $20M stated value of the Series B Preferred Stock brings stockholders' equity above the $2.5M minimum, but awaits formal Panel determination
- Company still needs to demonstrate compliance with the bid price rule by June 1, 2026 (extension requested to June 4, 2026)
- The acquired entity (Holdings) had no operations, employees, revenue, or material liabilities — only the patent portfolio
- Series B Preferred Stock carries a senior liquidation preference of $20M, is non-voting, non-redeemable, bears no dividends, and has no price-based anti-dilution
- Conversion is subject to a 4.99% beneficial ownership limitation (increasable to 9.99% on 61 days' notice)
- Company has covenanted to seek stockholder approval for conversion within 180 days post-closing, but failure to obtain it triggers no penalties or economic consequences
Financial Impact
$20,000,000 aggregate stated value of Series B Preferred Stock issued as merger consideration; no cash consideration paid; potential dilution of up to 13,333,333 common shares upon conversion (subject to stockholder approval and beneficial ownership limits)
Risk Factors
- Nasdaq Hearings Panel may not accept the Series B Preferred Stock as sufficient to demonstrate compliance with the stockholders' equity rule
- Accounting treatment of the Series B Preferred Stock may result in an equity component less than the $20M stated value
- Company still faces delisting risk if it cannot satisfy the bid price rule by June 1/4, 2026
- Stockholders may not approve the conversion proposal, leaving the Series B Preferred Stock permanently non-convertible
- Patents may be invalidated or impaired, potentially triggering IP clawback provisions that could result in forfeiture of consideration
- No revenue or operations associated with the acquired assets — value depends entirely on future R&D and patent prosecution outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-000653 |
| Document: e7595_8k.htm | 0001731122-26-000653 |
| Document: e7595_ex3-1.htm | 0001731122-26-000653 |
| Document: 0001731122-26-000653-index-headers.html | 0001731122-26-000653 |
| Document: 0001731122-26-000653-index.html | 0001731122-26-000653 |
| Document: 0001731122-26-000653.txt | 0001731122-26-000653 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | EFFECT | $0.2510 | awaiting T+1 | — | $0.2530 (−0.80%) |
Oct 22, 2026 5d ago | 8-K | $0.2946 $0.2750 | ▲ +6.65% | ▲ +7.36% | $0.2530 (+14.12%) |
Oct 15, 2026 12d ago | SC 13D/A | $0.6800 $0.4720 | ▲ +30.59% | ▲ +31.01% | $0.2530 (+62.79%) |
Oct 9, 2026 18d ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +9.70% | $0.2530 (+79.43%) |
Sep 29, 2026 28d ago | NT 10-K | $1.47 $1.38 | ▲ +6.12% | ▲ +6.30% | $0.2530 (+82.79%) |
Jun 17, 2026 18w ago | 8-K | $3.78 $4.15 | ▲ +9.79% | ▲ +10.10% | $0.2530 (−93.31%) |
Jun 16, 2026 19w ago | 8-K | $4.00 $3.78 | ▼ −5.50% | ▼ −6.28% | $0.2530 (−93.68%) |
May 20, 2026 22w ago | 8-K | $1.80 $2.32 | ▼ −28.89% | ▼ −28.69% | $0.2530 (+85.94%) |
May 1, 2026 25w ago | 8-K | $2.60 $2.50 | ▼ −3.88% | ▼ −4.68% | $0.2530 (−90.26%) |
Apr 28, 2026 26w ago | DEFA14A | $2.66 $2.64 | ▼ −0.90% | ▼ −1.92% | $0.2530 (−90.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers